The reiteration of a 'Market Outperform' rating and the maintenance of a $15 price target by a reputable analyst like Reni Benjamin could instill confidence in investors and positively influence Ambrx Biopharma's stock price in the short term. The specific mention of the company and the reaffirmation of the price target suggest a strong conviction in the company's performance and potential growth.